What do systematic reviews say?

Pericyazine vs Typical antipsychotics

It is very uncertain whether pericyazine changes adverse events ‐ for specific reasons ‐ Extrapyramidal side effect compared with typical antipsychotic (very low certainty).

• Pericyazine for schizophrenia 2014 · Cochrane Headline outcomes only
  RR 0.59 [0.38, 0.89]
  3 studies · 163 participants
  Very low

Intervention not reported

It is very uncertain whether the intervention changes adverse events (very low certainty).

• Gamma‐aminobutyric acid agonists for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
  RR 4.54
  9 studies · 284 participants
  Very low

Benzodiazepines vs phenobarbital (as active placebo)

It is very uncertain whether benzodiazepines changes adverse events: any compared with phenobarbital (as active placebo) (very low certainty).

• Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
  RR 1.53 [0.97, 2.41]
  1 study · 21 participants
  Very low

CHOLINERGIC DRUGS vs placebo

It is very uncertain whether CHOLINERGIC DRUGS changes adverse effects: Any adverse events compared with PLACEBO (very low certainty).

• Cholinergic medication for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
  RR 0.56 [0.15, 2.14]
  4 studies · 106 participants
  Very low

Switch to a specific antipsychotic vs switch to a different specific antipsychotic

• Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 80 participants
  Very low

Switch to a specific antipsychotic vs switch to a different specific antipsychotic

• Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 53 participants
  Low